Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom
The COVID-19 pandemic has given rise to numerous commercially available antigen rapid diagnostic tests (Ag-RDTs). To generate and to share accurate and independent data with the global community requires multisite prospective diagnostic evaluations of Ag-RDTs. This report describes the clinical eval...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2023
|
| _version_ | 1824459110281641984 |
|---|---|
| author | Thompson, CR Torres, PM Kontogianni, K Byrne, RL LSTM Diagnostic group Noguera, SV Luna-Muschi, A Marchi, AP Andrade, PS Dos Santos Barboza, A Nishikawara, M CONDOR steering group Body, R de Vos, M Escadafal, C Adams, E Figueiredo Costa, S Cubas-Atienzar, AI |
| author2 | Hayward, G |
| author_facet | Hayward, G Thompson, CR Torres, PM Kontogianni, K Byrne, RL LSTM Diagnostic group Noguera, SV Luna-Muschi, A Marchi, AP Andrade, PS Dos Santos Barboza, A Nishikawara, M CONDOR steering group Body, R de Vos, M Escadafal, C Adams, E Figueiredo Costa, S Cubas-Atienzar, AI |
| author_sort | Thompson, CR |
| collection | OXFORD |
| description | The COVID-19 pandemic has given rise to numerous commercially available antigen rapid diagnostic tests (Ag-RDTs). To generate and to share accurate and independent data with the global community requires multisite prospective diagnostic evaluations of Ag-RDTs. This report describes the clinical evaluation of the OnSite COVID-19 rapid test (CTK Biotech, CA, USA) in Brazil and the United Kingdom. A total of 496 paired nasopharyngeal (NP) swabs were collected from symptomatic health care workers at Hospital das Clínicas in São Paulo, Brazil, and 211 NP swabs were collected from symptomatic participants at a COVID-19 drive-through testing site in Liverpool, United Kingdom. Swabs were analyzed by Ag-RDT, and results were compared to quantitative reverse transcriptase PCR (RT-qPCR). The clinical sensitivity of the OnSite COVID-19 rapid test in Brazil was 90.3% (95% confidence interval [CI], 75.1 to 96.7%) and in the United Kingdom was 75.3% (95% CI, 64.6 to 83.6%). The clinical specificity in Brazil was 99.4% (95% CI, 98.1 to 99.8%) and in the United Kingdom was 95.5% (95% CI, 90.6 to 97.9%). Concurrently, analytical evaluation of the Ag-RDT was assessed using direct culture supernatant of SARS-CoV-2 strains from wild-type (WT), Alpha, Delta, Gamma, and Omicron lineages. This study provides comparative performance of an Ag-RDT across two different settings, geographical areas, and populations. Overall, the OnSite Ag-RDT demonstrated a lower clinical sensitivity than claimed by the manufacturer. The sensitivity and specificity from the Brazil study fulfilled the performance criteria determined by the World Health Organization, but the performance obtained from the UK study failed to do. Further evaluation of Ag-RDTs should include harmonized protocols between laboratories to facilitate comparison between settings |
| first_indexed | 2025-02-19T04:36:34Z |
| format | Journal article |
| id | oxford-uuid:933887b5-f97a-478c-a37d-f4c5310dd3f4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:36:34Z |
| publishDate | 2023 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:933887b5-f97a-478c-a37d-f4c5310dd3f42025-02-05T14:23:35ZMulticenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United KingdomJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:933887b5-f97a-478c-a37d-f4c5310dd3f4EnglishSymplectic ElementsAmerican Society for Microbiology2023Thompson, CRTorres, PMKontogianni, KByrne, RLLSTM Diagnostic groupNoguera, SVLuna-Muschi, AMarchi, APAndrade, PSDos Santos Barboza, ANishikawara, MCONDOR steering groupBody, Rde Vos, MEscadafal, CAdams, EFigueiredo Costa, SCubas-Atienzar, AIHayward, GThe COVID-19 pandemic has given rise to numerous commercially available antigen rapid diagnostic tests (Ag-RDTs). To generate and to share accurate and independent data with the global community requires multisite prospective diagnostic evaluations of Ag-RDTs. This report describes the clinical evaluation of the OnSite COVID-19 rapid test (CTK Biotech, CA, USA) in Brazil and the United Kingdom. A total of 496 paired nasopharyngeal (NP) swabs were collected from symptomatic health care workers at Hospital das Clínicas in São Paulo, Brazil, and 211 NP swabs were collected from symptomatic participants at a COVID-19 drive-through testing site in Liverpool, United Kingdom. Swabs were analyzed by Ag-RDT, and results were compared to quantitative reverse transcriptase PCR (RT-qPCR). The clinical sensitivity of the OnSite COVID-19 rapid test in Brazil was 90.3% (95% confidence interval [CI], 75.1 to 96.7%) and in the United Kingdom was 75.3% (95% CI, 64.6 to 83.6%). The clinical specificity in Brazil was 99.4% (95% CI, 98.1 to 99.8%) and in the United Kingdom was 95.5% (95% CI, 90.6 to 97.9%). Concurrently, analytical evaluation of the Ag-RDT was assessed using direct culture supernatant of SARS-CoV-2 strains from wild-type (WT), Alpha, Delta, Gamma, and Omicron lineages. This study provides comparative performance of an Ag-RDT across two different settings, geographical areas, and populations. Overall, the OnSite Ag-RDT demonstrated a lower clinical sensitivity than claimed by the manufacturer. The sensitivity and specificity from the Brazil study fulfilled the performance criteria determined by the World Health Organization, but the performance obtained from the UK study failed to do. Further evaluation of Ag-RDTs should include harmonized protocols between laboratories to facilitate comparison between settings |
| spellingShingle | Thompson, CR Torres, PM Kontogianni, K Byrne, RL LSTM Diagnostic group Noguera, SV Luna-Muschi, A Marchi, AP Andrade, PS Dos Santos Barboza, A Nishikawara, M CONDOR steering group Body, R de Vos, M Escadafal, C Adams, E Figueiredo Costa, S Cubas-Atienzar, AI Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom |
| title | Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom |
| title_full | Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom |
| title_fullStr | Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom |
| title_full_unstemmed | Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom |
| title_short | Multicenter diagnostic evaluation of onsite COVID-19 Rapid Test (CTK Biotech) among symptomatic individuals in Brazil and the United Kingdom |
| title_sort | multicenter diagnostic evaluation of onsite covid 19 rapid test ctk biotech among symptomatic individuals in brazil and the united kingdom |
| work_keys_str_mv | AT thompsoncr multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT torrespm multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT kontogiannik multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT byrnerl multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT lstmdiagnosticgroup multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT noguerasv multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT lunamuschia multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT marchiap multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT andradeps multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT dossantosbarbozaa multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT nishikawaram multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT condorsteeringgroup multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT bodyr multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT devosm multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT escadafalc multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT adamse multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT figueiredocostas multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom AT cubasatienzarai multicenterdiagnosticevaluationofonsitecovid19rapidtestctkbiotechamongsymptomaticindividualsinbrazilandtheunitedkingdom |